Press Releases
Samsung Biologics recognized for service excellence as it receives CDMO Leadership Awards for 11th consecutive year
Samsung Biologics received the 2024 CDMO Leadership Awards presented by Outsourced Pharma and Life Science Connect for its service and business excellence. The company has been awarded in all six performance categories: Quality, Reliability, Capabilities, Expertise, Compatibility, and Service Capabilities.
Attending the awards ceremony in New York on the sidelines of DCAT Week, Samsung Biologics said the recognition was a testament to the company’s unwavering commitment to client satisfaction.
“For Samsung Biologics, this recognition serves as a powerful motivator, propelling us forward in our continued commitment to ensuring the long-term success of our clients,” said Kevin Sharp, Senior Vice President and Head of Global Sales at Samsung Biologics. “Each category underscores the multifaceted nature of our partnerships, making this acknowledgment particularly meaningful.”
Samsung Biologics commenced full operations at Plant 4, the world’s largest single biomanufacturing facility, in June 2023 and broke ground on its second Bio Campus with the construction of Plant 5. The company also plans to complete the construction of a standalone antibody-drug conjugate (ADC) facility within this year and has been investing in biotech companies with promising ADC technologies, as part of continued efforts to diversify its portfolio. Samsung Biologics has also optimized its development services with customizable CMC solutions incorporating its proprietary platforms to accommodate clients’ evolving needs while ensuring quality.
The CDMO Leadership Awards, now in its 13th year, offers accurate and reliable customer feedback to provide support in choosing a reputable partner for development and manufacturing needs. Samsung Biologics has won the award for 11 consecutive years.
“Drug and therapy sponsors had much to be concerned with the last 12 months or so. There was still supply-chain uncertainty, ever-growing novelty in platforms and processes requiring new skillsets and technologies, and the speed of everything seemed to accelerate,” said Louis Garguilo, Chief Editor and Conference Chair of Outsourced Pharma. “Through it all, CDMOs stayed focused, and also adapted to customer and market needs. CDMOs may not have had all the answers in an uncertain year, but these are the external partners who provided the biopharma industry with the best solutions.”
Samsung Biologics received the 2024 CDMO Leadership Awards presented by Outsourced Pharma and Life Science Connect for its service and business excellence. The company has been awarded in all six performance categories: Quality, Reliability, Capabilities, Expertise, Compatibility, and Service Capabilities.
Attending the awards ceremony in New York on the sidelines of DCAT Week, Samsung Biologics said the recognition was a testament to the company’s unwavering commitment to client satisfaction.
“For Samsung Biologics, this recognition serves as a powerful motivator, propelling us forward in our continued commitment to ensuring the long-term success of our clients,” said Kevin Sharp, Senior Vice President and Head of Global Sales at Samsung Biologics. “Each category underscores the multifaceted nature of our partnerships, making this acknowledgment particularly meaningful.”
Samsung Biologics commenced full operations at Plant 4, the world’s largest single biomanufacturing facility, in June 2023 and broke ground on its second Bio Campus with the construction of Plant 5. The company also plans to complete the construction of a standalone antibody-drug conjugate (ADC) facility within this year and has been investing in biotech companies with promising ADC technologies, as part of continued efforts to diversify its portfolio. Samsung Biologics has also optimized its development services with customizable CMC solutions incorporating its proprietary platforms to accommodate clients’ evolving needs while ensuring quality.
The CDMO Leadership Awards, now in its 13th year, offers accurate and reliable customer feedback to provide support in choosing a reputable partner for development and manufacturing needs. Samsung Biologics has won the award for 11 consecutive years.
“Drug and therapy sponsors had much to be concerned with the last 12 months or so. There was still supply-chain uncertainty, ever-growing novelty in platforms and processes requiring new skillsets and technologies, and the speed of everything seemed to accelerate,” said Louis Garguilo, Chief Editor and Conference Chair of Outsourced Pharma. “Through it all, CDMOs stayed focused, and also adapted to customer and market needs. CDMOs may not have had all the answers in an uncertain year, but these are the external partners who provided the biopharma industry with the best solutions.”